 |
|
 |
|
|
Resources for AML from GrannyBarb and Art's Leukemia Links
| | | General Information | |
- The NCI PDQ patient statement on acute myeloid leukemia for adults .
- The NCI PDQ physician statement on acute myeloid leukemia for adults .
- The NCI PDQ patient statement on acute myeloid leukemia for children .
- The NCI PDQ physician statement on acute myeloid leukemia for children .
- BMTs for acute Myelogeneous Leukemia from BMT Newsletter September 1994 (Issue #25).
- The Leukemia Information Center , information about Acute Myeloid Leukemia, from Medicine Online . This page sponsered by Pharmacia & Upjohn makers of Idamycin has a wealth of information on AML for both consumers and healthcare professionals.
-
Leukemia from ACOR's Pediatric
Oncology Resources , gives an overview of diagnosis
and treatment of pediatric leukemia. Links to news to
other information and stories of childhood leukemia
survivors.
-
Acute Myeloid Leukemia (AML) a booklet from the
Leukemia and Lymphoma
Society of America which aims to provide
information about AML to patients and their families. It
can also be downloaded as a
PDF file or in Spanish:
Leucemia Mieloide Aguda .
- Understanding Acute Myeloblastic Leukaemia (AML) a basic introduction to AML from CancerbACUP an organization in England that aims to help people live with cancer by providing information, emotional support and counselling.
- The Childhood Leukemia Center , an excellent site, Not to be missed! . It provides lots of useful information about dealing with Childhood Leukemia. The material in this Center has been excerpted or adapted from Childhood Leukemia: A Guide for Families, Friends, and Caregivers by Nancy Keene , third edition, copyright 2002 by O'Reilly & Associates, Inc. . Information includes a FAQ on childhood leukemia , an explanation of blood counts , practical tips for parents of children with leukemia and more. Although this site is oriented towards childhood leukemia, there is useful infomation about adult leukemia too.
- Acute Myelogenous Leukemia by Karen Seiter, MD, from the eMedicine World Medicine Library . This is a very technical review of the symptoms, causes, diagnosis and treatment of adult AML .
- Acute Myelocytic Leukemia (also called Acute Myelogenous Leukemia) by Mark E. Weinblatt, MD, from the eMedicine World Medicine Library . This is a very technical review of the symptoms, causes, diagnosis and treatment of pediatric AML .
- Acute Myeloid Leukemia from CancerConsultants.com is an overview of the treatment of AML for patients.
 | | | Journal articles and abstracts on AML |
|
Included here are
articles and abstracts from journals on Acute Myeloid
Leukemia. articles are are listed in reverse chronological
order (most recent articles first).
-
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia
with a Normal Karyotype, New
England Journal of Medicine , August 21, 2003,
Volume 352, No. 3, pages 254-266 by Brunangelo Falini,
et. al. for the GIMEMA Acute Leukemia Working Party.
(The full article will be available for free 6 months
after publication, registration is required, until then the
article abstract is available.) This study of
patients with AML found that nucleophosmin (NPM), a
nuclear protein, was displaced into the cytoplasm in
about 60 percent of patients with a no chromosomal
abnormalities (normal karyotype) and predicted a good
response to induction chemotherapy.
-
Effect of Priming with Granulocyte Colony-Stimulating
Factor on the Outcome of Chemotherapy for Acute Myeloid
Leukemia , New
England Journal of Medicine , August 21, 2003,
Volume 349, No. 8, pages 743-752 by Bob Löwenberg,
et. al. Patients were randomly assigned to get ordinary
induction and consolidation chemotherapy, half with
G-CSF (Neupogen) given concurrently and half
without. The patients who recieved G-CSF had a higher
rate of disease-free survival at 4 years. Patients with
standard-risk AML had better overall survival at 4
years.
-
Acute Myeloid Leukemia by Richard M. Stone, Margaret
R. O'Donnell and Mikkael A. Sekeres from Hematology , American
Society of Hematology Education Program Book ,
2004. This article summarizes the current state of the
Art for treating AML in adults, with seperate sections
for younger adults (under 60) and older adults (60 and
over). It discusses the optimal choice of induction and
postremission therapy, the role of allogeneic and
autologous transplants as well as newer therapies that
are being developed. Also see
Acute Myeloid Leukemia, by Frederick R. Appelbaum, Jacob
M. Rowe, Jerald Radich and John E. Dick from 2001
edition. This articles includess a summary of the
current state-of-the-art therapy for adult AML,
discusses the fact that AML is not a single disease, but
a number of related diseases each distinguished by
unique cytogenetic markers, looks at how these unique
cytogenetic markers provide the opportunity to develop
targeted therapies. It also includes newer
immunotherapeutic approaches to treating AML, including
the use of antibody-based treatments.
-
Realistic Pathologic Classification of Acute Myeloid Leukemias
, by Arber, Daniel A. from the
American Journal of Clinical Pathology , April 2001, Volume 115,
Number 4. This is very technical discussion of a more clinically
meaningful classification scheme for AML. Other classification
criteria are the current French-American-British (FAB) system and a
recently proposed World Health Organization (WHO)
classification.
- Therapy of Acute Myeloid Leukemia by Martin S. Tallman, from Cancer Control: Journal of the Moffitt Cancer Center , Vol 8, No. 1, 2001. This article is a review of the current treatment options for AML and the current thinking of the prognosis for AML patients.
- Core Binding Factor (CBF) Primary Acute Myeloid Leukemia: Biology and Clinical Implications , Marcucci Guido, et. al. from Medscape Oncology, March/April 2000, Volume, 3 Number 2. Discusses AML with a translocation (8;21)(q22;q22) or inversion of chromosome 16. These genomic abnormalities disrupt the genes for core binding factor (CBF) and have a favorable prognosis. This review discusses the molecular biology and clinical management of primary AML with these abnormalities.
- Recent Advances in the Biology and Management of Primary Acute Myeloid Leukemia with Rearrangements of the MLL Gene , Strout, Matthew P., et. al., from Medscape Oncology, May/June 2000, Volume, 3 Number 3. Discusses the detection of the Myeloid-Lymphoid Leukemia or Mixed Lineage Leukemia (MLL) gene in patients with AML and the prognostic significance of this finding.
- Novel Therapeutic Targets and Strategies in Acute Leukemia and MDS by Richard M. Stone, M.D., describes new treatments for AML and Myelodysplastic Syndrome, including Programmed Cell Death, Inhibiting Angiogenesis, and Immunotherapy. This is a summary of articles presented at the 41th Annual American Society of Hematology Meeting, December, 1999.
- Total-Body Irradiation and Melphalan Is a Safe and Effective Conditioning Regimen for Autologous Bone Marrow Transplantation in Children With Acute Myeloid Leukemia in First Remission , Bonetti F., et. al., Journal of Clinical Oncology , Vol 17, Issue 12, December, 1999, pages 3729-3735.
- Management of
Acute Myeloid Leukemia in Elderly Patients , Hiddemann W.,
et. al., Journal of Clinical
Oncology , Vol 17, Issue 11, November, 1999, pages
3569-3576. This article argues that in general, intensive therapy for
AML at older age seems to be a better treatment then supportive
care.
-
Chemotherapy Compared with autologous or allogeneic Bone Marrow
Transplantation in the Management of acute Myeloid Leukemia in First
Remission , New England Journal
of Medicine December 3, 1998, Vol. 339, No. 23, page 1649 by
Peter a. Cassileth, et. al. (registration, which is free is
required). also an accompanying editorial
Transplantation in First Remission of acute Myeloid Leukemia ,
by alan K. Burnett, in the same edition.
autologous marrow transplantation for AML has no survival advantage
an article from Reuters Health via Intelihealth on these
findings. a review of this article by Kenneth Blank of University of
Pennsylvania Cancer Center is available on Oncolink , the article is OncoLink
Journal Scan: Chemotherapy Compared with autologous or allogeneic Bone
Marrow Transplantation in the Management of acute Myeloid Leukemia in
First Remission . Followup Correspondence: Treatment
of acute Myeloid Leukemia from the May 6, 1999 issue, Vol. 340,
No. 18, page, 1436.
- Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype (article abstract) by Bloomfield, et. al. Cancer Research September 15 1998, Volume 58 No. 18, page 4173. Reports on long term (median 7 year) survival of AML patients treated with various doses of Ara-C (cytarabine). Also see Cure Rate Soars In Some AML Patients Receiving High-Dose Cytarabine from The Doctor's Guide to the Internet .
- Platelet
Transfusions during the treatment of Acute Myeloid Leukemia . The
December 25, 1997 issue, (Volume 337, Number 26) of the New England Journal of Medicine has
two articles plus an editorial on the use of platelet transfusions in
the treatment of AML (to read the articles registration is required
but is free).
- The
threshold for prophylactic platelet transfusions in adults with acute
myeloid leukemia , by Rebulla P, Finazzi G, Marangoni F, et
al. pages 1870-5.
-
Editorial: The Perils of Platelet Transfusions , by Margot
S. Kruskall, page, 1914, discusses the history and uses of platelet
tranfusions.
-
Prophylactic Platelet Transfusions in Acute Myeloid Leukemia ,
followup correspondence from the May 14, 1998 issue, Volume 338,
Number 20 .
-
Comparison of Autologous Bone Marrow Transplantation and Intensive
Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
, by Harousseau, Jean-Luc et. al., Blood , Vol. 90 No. 8 (October
15), 1997: pp. 2978-2986. This article compares the results of
autologous BMT, with allogeneic BMT and intensive consolidation
chemotherapy in approximately 500 patients treated in Europe between
November, 1987 and May, 1994.
- Mitoxantrone Is Effective in Elderly Patients with aNLL , Drugs & Therapy Perspectives . Describes treatment of elderly AML patients (over 60) primarily with Mitoxantrone.
- Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults , by Ruben A. Saez, MD, from Cancer Control: Journal of the Moffitt Cancer Center , Vol 4, No. 5, 1997. Several advances in evaluation and treatment have improved the prognosis of adults with acute myelogenous leukemia. A good overview of current treatment options for adults with AML.
- Acute Myeloid Leukemia , Boyer K: The Internet Journal of Academic Physician Assistants 1997;. This is a technical but readable overview of diagnosis, and treatment of AML. It is somewhat out-of-date.
- ABC of clinical haematology:The acute leukaemias , a review article by R J Liesner and A H Goldstone, from the British Medical Journal , Vol 314, page 733, 1 March 1997.
- NCCN Acute Leukemia Practice Guideline , practice guidelines from The Acute Leukemia Practice Guidelines Committee of the National Comprehensive Cancer Center (NCCN)-affiliated network, November 1996. Provides guidelines for the diagnosis and treatment of AML.
- The use of
growth factors during the treatment of AML in elderly patients.
The June 22, 1995 issue (Volume 332, No. 25) of the New England Journal of Medicine , has
two articles and an editorial on the use of growth factors (GM-CSF
which is called Leukine and G-CSF which is called Neupogen) after
induction chemotherapy for AML in the elderly (over age 60 in one
group, over 65 in the other). Both studies showed that there although
the period of neutropenia was shortened with the use of these drugs,
overall survival was not significantly different (to read the articles
registration is required but is free)
- Autologous
or Allogeneic Bone Marrow Transplantation Compared with Intensive
Chemotherapy in Acute Myelogenous Leukemia , New England Journal of Medicine
January 26, 1995, Vol. 332, No. 4, page 217, by Robert a. Zittoun,
et. al. (registration is required but is free). also an accompanying
editorial
Post-Remission Treatment of Acute Myelogenous Leukemia by Bob
Lowenberg in the same edition. Followup Correspondence: Treatment
of Acute Myelogenous Leukemia from the June 22, 1995 issue,
Vol. 332, No. 25, page, 1717.
- Intensive Postremission Chemotherapy In adults with acute Myeloid Leukemia , New England Journal of Medicine October 6, 1994, Vol. 331, No. 14, page 896 by Robert J. Mayer, et. al. (registration, which is free is required) also an accompanying editorial Intensified Therapy for acute Myeloid Leukemia by James F. Bishop, in the same edition. Followup Correspondence: Post-remission Chemotherapy for acute Myeloid Leukemia from the February 2, 1995 issue, Vol 332, Number 5, page, 334.
| | | Other articles | |
- Gemtuzumab Zogamicin (also called CMA-676, to be marketed as Mylotarg) was recommended by the Oncologic Drugs Advisory Committee (ODAC) to the FDA for limited approval (in patients over 60) for the treatment of relapsed AML, on March 17, 2000. The FDA approved Mylotarg in May, 2000 for patients over 60 with relapsed AML who were not good candidates for conventional chemotherapy. Here are some articles on Gemtuzumab:
- To BMT or to not BMT for AML . This is my analysis of whether or not to have an allogeneic BMT for AML in first remission.
|
Acute Promyelocytic Leukemia
| | Journal articles and abstracts on APL |
|
-
Complete Remission after Treatment of Acute
Promyelocytic Leukemia with Arsenic Trioxide ,
New England Journal of
Medicine , November 5, 1998, Vol. 339, No. 19, page
1341, by Steven L. Soignet, et. al. (registration, which
is free is required). Describes initial experiences with
using Arsenic Trioxide to treat relapsed Acute
Promyelocytic Leukemia (APL). also an accompanying
editorial
Arsenic -- New Life for an Old Potion by Robert
E. Gallagher in the same edition. also see the followup
correspondence from the april 1, 1999, Volume 340,
Number 13 issue:
Treatment of Acute Promyelocytic Leukemia with Arsenic
Trioxide .
-
Journal Manuscript Review: All-trans-Retinoic Acid for
Acute Promyelocytic Leukemia , from Medscape , a review
of the article by
Tallman, et. al., October 9, 1997 -- Volume 337, Number
15 . (registration, which is free is required), as
well as an accompanying editorial,
Differentiation Therapy for Acute Promyelocytic Leukemia
in its entirety. Also see the followup
correspondence from the February 5, 1998, Volume 338,
Number 6 issue:
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia.
- Treatment of
Newly Diagnosed Acute Promyelocytic Leukemia Without Cytarabine
, from Journal of
Clinical Oncology 15:483-490. By Elihu Estey, Peter F. Thall,
Sherry Pierce, Hagop Kantarjian, and Michael Keating. Only the
abstract of the article is available.
- Management of acute promyelocytic leukemia relapse in the ATRA era Carlo Castagnola, Monia Lunghi, alessandro Corso, Monica Tajana, Patrizia Zappasodi, Melissa Dabusti, Mario Lazzarino, Carlo Bernasconi, article abstract only, haematologica , 1998 ; 83 : 714-717.
- All-Trans-Retinoic acid and Pseudotumor Cerebri in a Young adult with Acute Promyelocytic Leukemia: a Possible Disease association Giuseppe Visani, Giovanni Bontempo, Silvia Manfroi, alberto Pazzaglia, Roberto D'alessandro, Sante Tura article abstract only Haematologica 1996; 81:152-154.
| | | Other articles on Acute Promyelocytic Leukemia (APL) | |
|
|
